Clinical Trial Update: Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two regimens of a rebeccamycin analogue in patients with advanced or recurrent non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rebeccamycin analogue (rebeccamycin analogue)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED